NOV 08, 2017 12:00 PM PST

Combined immunohistochemistry and RNA in situ hybridization to elucidate tumor molecular heterogeneity in prostate cancer

SPONSORED BY: Advanced Cell Diagnostics
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate Scientist, Henry Ford Health System
    Biography
      Dr. Palanisamy completed his undergraduate and graduate studies at the University of Madras, India, and is currently an Associate/Senior Scientist at the Henry Ford Health System. He also holds an adjunct faculty appointment with the Michigan Center for Translational Pathology (MCTP) at the University of Michigan. His current research program is focused on the discovery of cancer biomarkers in lymphomas and solid cancers. During his post-doctoral research at the Memorial Sloan-Kettering Cancer Center, Dr. Palanisamy's work contributed to the discovery of recurrent gene fusions in follicular and diffuse large B-cell lymphomas. He was the founding Director of Research and Development at the Cancer Genetics, Inc (CGIX), where he introduced novel approaches to develop diagnostic reagents targeting chromosomal translocations in cancer. Dr. Palanisamy pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered novel "druggable" gene fusions in prostate cancer, gastric cancer, and melanoma (Palanisamy et al., Nat Med 2010). His current research aims to understand the molecular basis of tumor heterogeneity in solid cancers, with particular focus on prostate cancer, and its impact in early diagnosis, response to treatment, and clinical outcome.

    Abstract:

    Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors are highly heterogeneous and there are many studies evaluating the molecular profile or ‘fingerprint’ of prostate cancer.  Conventional analysis reviews the protein expression of key markers via serum analysis and immunohistochemistry (IHC) of the biopsy.  In this presentation we will review how RNA in situ hybridization (ISH) analysis of prostate cancer can unravel the molecular heterogeneity of the tumor, identify molecular subsets and detect key fusions and mutations of the RNA.  We will also present a comparison of IHC and ISH technology and the combination of dual color IHC and dual color ISH can be used to enhance simultaneous evaluation of DNA, RNA and protein, revealing the molecular profile of prostate cancer.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    AUG 16, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 16, 2018 08:00 AM PDT
    DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    Loading Comments...